Currently, HER2-amplified breast cancers are treated with monoclonal antibodies against the tyrosine kinase receptor such as trastuzumab, alone or coupled to emtansine, a cytotoxic agent (T-DM1). Here, NTRK1 is linked to breast carcinoma.